Drug Details
General Information of the Drug (ID: DR3286) | ||||
---|---|---|---|---|
Name |
FTY720
|
|||
Synonyms |
Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty 720; Fty-720; Fingolimod (hydrochloride); Fingolimod (FTY720) HCl; 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; FTY720 free base; CHEBI:63112; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol;hydrochloride; G926EC510T; MFCD00939512; Gilenya (TN); 1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-, hydrochloride; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; 1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-, hydrochloride (1:1); FTY720 hydrochloride; Fingolimod-d4 Hydrochloride; 2-amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride.; 1,3-Propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-, hydrochloride; 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol hydrochloride; 2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol, hydrochloride; Fingolimod hydrochloride [USAN]; Fingolimod (FTY720); Imusera; 2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride; Fingolimod, HCl; FTY720,Fingolimod; Fin;limod hydrochloride; PubChem23815; FTY720 - Fingolimod; Fingolimod HClFTY-720; Epitope ID:156573; SCHEMBL81362; cc-329; MLS006010179; Fingolimod (FTY-720 HCl); FTY-720 HYDROCHLORIDE; CHEMBL544665; FTY-720A; Fingolimod hydrochloride FTY720; AOB7477; DTXSID00167364; EX-A960; TDI-132; 2-Amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol, HCl; BCPP000225; BCP01808; Fingolimod hydrochloride (JAN/USAN); s5002; AKOS005145784; AC-1929; AM84549; BCP9000705; CCG-265016; CS-0114; KS-1172; AK-33554; HY-12005; SMR004701287; SY057854; AB0018286; DB-014816; A8548; F1018; FT-0643569; SW219384-1; 162359-56-0 (HCl); EC-000.2314; A25158; D04187; J10426; W-5231; 359F560; SR-01000942237; Q-101363; SR-01000942237-2; Q27132395; 2-(4-octylphenethyl)-2-aminopropane-1,3-diol hydrochloride; 2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol hydrochloride; 2-Amino-2-[2-(4-octylphenyl)-ethyl]-1,3-propanediol hydrochloride; 2-Amino-2-[2-(4-n-octylphenyl)ethyl]propane-1,3-diol Hydrochloride; 2-Amino-2-[2-(4-octyl-phenyl)-ethyl]-propane -1,3-diol hydrochloride; 2-Amino-2-[2-(4-octyl-phenyl)-ethyl]-propane-1,3-diol hydrochloride
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Psychoactive substances use disorder [ICD-11: 6C4G] | Phase 1 | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C19H34ClNO2
|
|||
PubChem CID | ||||
Canonical SMILES |
CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl
|
|||
InChI |
1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H
|
|||
InChIKey |
SWZTYAVBMYWFGS-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 162359-56-0
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Vitamin E | Salmo salar | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | HMOX1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | SOD Cu-Zn | Molecule Info |
Pathway MAP
|
||
In-vivo Model | Sprague-Dawley rats were used in this study. | |||||
Experimental
Result(s) |
Pre treatment with FTY720 combined with vitamin E exerts synergistic neuroprotective effects in the simulated cerebral ischemia in vitro. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Dopamine D3 receptor (D3R) | Molecule Info | [3] | |
Sphingosine kinase 1 (SPHK1) | Molecule Info | [4] | ||
BioCyc | Sphingosine and sphingosine-1-phosphate metabolism | Click to Show/Hide | ||
KEGG Pathway | Neuroactive ligand-receptor interaction | Click to Show/Hide | ||
2 | Dopaminergic synapse | |||
3 | Sphingolipid metabolism | |||
4 | Metabolic pathways | |||
5 | Calcium signaling pathway | |||
6 | Sphingolipid signaling pathway | |||
7 | VEGF signaling pathway | |||
8 | Fc gamma R-mediated phagocytosis | |||
9 | Tuberculosis | |||
NetPath Pathway | TCR Signaling Pathway | Click to Show/Hide | ||
2 | TNFalpha Signaling Pathway | |||
Panther Pathway | Angiogenesis | Click to Show/Hide | ||
2 | VEGF signaling pathway | |||
Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | Click to Show/Hide | ||
2 | Beta3 integrin cell surface interactions | |||
3 | S1P1 pathway | |||
4 | Sphingosine 1-phosphate (S1P) pathway | |||
5 | PDGFR-beta signaling pathway | |||
Reactome | Dopamine receptors | Click to Show/Hide | ||
2 | G alpha (i) signalling events | |||
3 | Sphingolipid de novo biosynthesis | |||
4 | VEGFR2 mediated cell proliferation | |||
WikiPathways | Monoamine GPCRs | Click to Show/Hide | ||
2 | GPCRs, Class A Rhodopsin-like | |||
3 | GPCR ligand binding | |||
4 | GPCR downstream signaling | |||
5 | Nicotine Activity on Dopaminergic Neurons | |||
6 | GPCRs, Other | |||
7 | Signal Transduction of S1P Receptor | |||
8 | Protein folding | |||
9 | Sphingolipid Metabolism |